PC
COGT icon

Pier Capital’s Cogent Biosciences COGT Stock Holding History

Pier Capital’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.31M Buy
188,951
+87,647
+87% +$3.07M 0.97% 50
2026
Q1 		$3.9M Buy
101,304
+55,044
+119% +$2.03M 0.64% 76
2025
Q4 		$1.64M Buy
+46,260
New +$1.3M 0.26% 96

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Pier Capital's COGT Position: Q2 2026 in Review

Pier Capital increased its Cogent Biosciences (COGT) stake by 87% in Q2 2026, buying an estimated $3.07M and bringing the position to 188,951 shares worth $7.31M. The position accounts for 0.97% of the portfolio, ranked #50.

Pier Capital first reported a position in COGT in Q4 2025 and has held it in 3 quarters since. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Pier Capital held 188,951 shares of Cogent Biosciences worth $7.31M as of Q2 2026.
  • Pier Capital bought 87,647 Cogent Biosciences shares in Q2 2026, an estimated $3.07M.
  • Cogent Biosciences made up 0.97% of Pier Capital's portfolio in Q2 2026, its #50 holding.
  • Pier Capital first reported a position in Cogent Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Pier Capital's 13F filing for Q2 2026, filed 5 Aug 2026.